Wegovy Injection Amounts: What the Evidence Tells Us About Each Dose

The dose ladder: what each injection amount is actually for

The STEP 1 trial didn't start participants on 2.4 mg. It followed the licensed titration schedule precisely, and that matters: the lower amounts in the Wegovy sequence exist to reduce gastrointestinal side effects, not to produce weight loss on their own. The 0.25 mg starting injection is an acclimatisation dose. Your gut, which processes semaglutide through GLP-1 receptors that slow gastric emptying, needs a settling-in period.

From 0.25 mg, the schedule moves to 0.5 mg, then 1.0 mg, then 1.7 mg, with roughly four weeks at each level before the prescriber reviews and advances. The 2.4 mg maintenance amount is where the therapeutic effect consolidates. The NHS semaglutide medicines page sets out this sequence clearly for patients and is a reliable first reference if you want the prescribing details in plain language.

One practical habit worth building from day one: before each injection, hold the pen up to a light source and check that the liquid is clear and colourless. Cloudiness or visible particles are a reason to contact your prescriber rather than use the pen. Takes under a minute and is listed in the Patient Information Leaflet as standard practice.

The 7.2 mg injection amount, what the MHRA approval actually means

On 14 April 2026, the MHRA approved a dedicated single-dose 7.2 mg Wegovy pen: one pre-set weekly injection, an auto-dosing mechanism, a built-in covered needle that locks after use. Trials at this higher amount reported around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide's headline figures. That is a meaningful clinical step forward for semaglutide.

The licence is specific, though. The 7.2 mg amount is approved for adults with a BMI of 30 or above, it is not licensed for people in the 27–29.9 range with a weight-related condition, which the 2.4 mg licence covers. It also does not extend to the cardiovascular risk-reduction indication. The starting dose remains 0.25 mg; 7.2 mg is reached by the same step-by-step titration, not by jumping straight in. If you are currently on treatment and wondering whether this higher amount might apply to you, that conversation belongs with your prescriber. For context on how the amount in each Wegovy pen is structured across the different devices, that page goes into the hardware detail.

Availability of specific doses and pen formats is confirmed at consultation, no page on this site claims to guarantee which pen is in stock at any given time.

Side effects are dose-related, and the pattern is predictable

Nausea, loose stools, constipation, indigestion and fatigue cluster around dose increases. The clinical picture from STEP 1 was consistent: gastrointestinal effects were most common in the first weeks after moving up an injection amount, with most participants finding they eased as the weeks passed. This is a reason the titration schedule exists, moving up too quickly raises the chance of stopping treatment because of side effects that would have resolved had there been more time at the lower amount.

Serious but infrequent: the MHRA's guidance on GLP-1 medicines highlights acute pancreatitis as a known risk. Severe stomach pain spreading to the back, with or without vomiting, is a reason to stop the injection and get urgent medical help. The same applies to signs of a serious allergic reaction. You can report any suspected side effect through the Yellow Card scheme, run by the MHRA, which actively monitors safety data across the full licensed population. If a side effect feels unmanageable at a given injection amount, contact your prescriber before changing anything yourself, dropping a dose or skipping a week is a clinical decision, not a self-management one.

Wegovy is not licensed in pregnancy, during breastfeeding, or for anyone trying to conceive. It is not licensed under the age of 18. People with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome need to discuss this with a prescriber before starting. These exclusions apply at every injection amount in the schedule.

Private access and what eligibility looks like at each amount

The Wegovy injection amounts a prescriber will consider depend first on whether you meet the licensed eligibility criteria: a BMI of 30 or above, or a BMI between 27 and 29.9 alongside a qualifying weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Meeting those criteria doesn't mean automatic progression to the highest dose, your starting amount and pace of titration reflect your individual clinical picture.

On the NHS, Wegovy is available through specialist weight management services under NICE guidance, with waiting lists that can be long. Private prescribing through a regulated online pharmacy is a separate route for people who don't meet NHS criteria or prefer not to wait. If you are weighing up the costs involved, the Wegovy price page gives an honest account of what private treatment typically involves. For a broader look at licensed weight-loss options, this overview of injectable weight-loss medicines covers what is and isn't licensed in the UK for weight management, worth reading if you have heard about related medicines that aren't actually licensed for weight loss here.

Understanding how a Wegovy injection works in practice is useful before starting. If you want to read about what the full course of Wegovy injections involves from start to finish, including what to expect at each stage, that page covers the journey in detail. You can also find specific guidance on how individual Wegovy injection steps are administered, which is worth reviewing before you handle the pen for the first time. If you are exploring whether this treatment suits your situation, checking your eligibility with our prescribers is the natural next step. Every consultation at nume is reviewed the same day by a named, GPhC-registered prescriber, a real clinician reads your answers, not software. Our clinical team's approach is set out on the clinical team page if you want to know more before starting.